A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of MIL93 in Advanced or Metastatic Solid Tumors
Latest Information Update: 18 Mar 2024
At a glance
- Drugs MIL 93 (Primary)
- Indications Adenocarcinoma; Gallbladder cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Beijing Mabworks Biotech
- 11 Mar 2024 Planned End Date changed from 1 Aug 2023 to 1 Aug 2025.
- 11 Mar 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2025.
- 16 Mar 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Aug 2023.